Discovery of a potent small molecule SIRT1/2 inhibitor with anticancer effectsopen access
- Authors
- Choi, Gildon; Lee, Jongkook; Ji, Jeong Yeon; Woo, Jimin; Kang, Nam Sook; Cho, Sung Yun; Kim, Hyoung Rae; Ha, Jab Du; Han, Sun-Young
- Issue Date
- Oct-2013
- Publisher
- SPANDIDOS PUBL LTD
- Keywords
- SIRT1; SIRT2; toxoflavin; anticancer agent
- Citation
- INTERNATIONAL JOURNAL OF ONCOLOGY, v.43, no.4, pp.1205 - 1211
- Indexed
- SCIE
SCOPUS
- Journal Title
- INTERNATIONAL JOURNAL OF ONCOLOGY
- Volume
- 43
- Number
- 4
- Start Page
- 1205
- End Page
- 1211
- URI
- https://scholarworks.bwise.kr/gnu/handle/sw.gnu/20431
- DOI
- 10.3892/ijo.2013.2035
- ISSN
- 1019-6439
- Abstract
- SIRT1 and SIRT2 are deacetylase enzymes that belong to the sirtuin family and are involved in tumorigenesis. In our screen for small molecules inhibiting SIRT1/2 toxoflavin was identified. Toxoflavin potently inhibited SIRT1 activity in in vitro deacetylase assay using purified SIRT1 protein. SIRT2 activity was also inhibited by toxoflavin less potently than SIRT1 in deacetylase assay in vitro. Toxoflavin exhibited growth inhibition of various cancer cell lines including A549 lung cancer cells with a GI(50) of 48 nM. Toxoflavin treatment in A549 cells increased the acetylated form of p53, which is a substrate of SIRT1. The acetylation levels of alpha-tubulin, a SIRT2 substrate, were also increased by toxoflavin treatment dose-dependently. Several toxoflavin derivatives were synthesized to determine the preliminary structure-activity relationship of toxoflavin. Some of the toxoflavin derivatives showed highly selective inhibition against SIRT1. In conclusion, this study presented toxoflavin as a potent SIRT1/2 inhibitor with anticancer activity.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 약학대학 > 약학과 > Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.gnu.ac.kr/handle/sw.gnu/20431)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.